International Stem Cell Corporation (ISCO) Pushing Forward with Regenerative Therapies
There is scant doubt that International Stem Cell Corporation’s (OTCQB: ISCO) attention and energy have been focused on creating advances in the field of regenerative medicine. On the contrary, ISCO continues to break new ground in settings where cells are being considered for use or are already being used in research and therapy. ISCO’s development and application of parthenogenesis, an impressive new stem cell technology, is a clear case in point. Parthenogenesis is a stem cell development process that tackles the problem of immune-rejection. The process uses unfertilized human eggs to create a new class of specialized, pluripotent human stem…